ClearPoint Neuro, Inc. reported record quarterly revenue of $8.5 million for the first quarter ended March 31, 2025, marking an 11% increase year-over-year compared with the first quarter of 2024. This growth was significantly driven by consumable product sales.
Total consumable product revenue experienced a substantial increase of $2.6 million year-over-year, or 104%. This category includes biologics and drug delivery cannulas, SmartFrame® Family Navigation devices, and ClearPoint PRISM® Laser Therapy Applicators, indicating strong adoption of key offerings.
The Biologics and drug delivery segment saw revenue increase 9% to $4.7 million, fueled by a 222% surge in product revenue to $1.8 million. The Neurosurgery navigation and therapy segment also demonstrated robust growth, with revenue surging 70% to $3.3 million. The company reaffirmed its full year 2025 revenue guidance of $36 million to $41 million, representing 15% to 31% growth over 2024, and reiterated its belief that a cash flow breakeven quarter is possible by the end of 2025, despite an increase in operational cash burn to $6.2 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.